Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence83
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma54
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma52
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma39
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia37
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?36
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs34
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence32
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects27
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review27
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review26
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis24
Current status and novel insights into the role of metastasectomy in the era of immunotherapy24
Progress in histology specific treatments in soft tissue sarcoma22
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan22
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes21
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer20
Importance of radiation-related cognitive decline in older adults who receive cranial radiation19
0.064298868179321